Result of General Meeting And Total Voting Rights
06 June 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces, further to the announcement of 6 May 2022, the passing of the Resolution at the General Meeting held earlier today. The Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Wednesday 8 June 2022.
The vote for the Resolution was carried out as a poll on the basis of proxies received and the votes of those present (11,815,745 for and 1,179,038 against, with 82,576 votes withheld), and on the basis of such poll it was resolved that the Resolution as contained in the Notice be passed as a Special Resolution.
Total Voting Rights
With effect from Admission the Company will have 237,685,180 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.
|Omega Diagnostics Group PLC||www.omegadx.com|
|Jag Grewal Chief Executive Officer||via Walbrook PR|
|Chris Lea, Chief Financial Officer|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)|
|Alice Lane/ Harriet Ward (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Applegarth||Mob: 07584 391 303|
|Sam Allen||Mob: 07502 558 258|
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health. www.omegadx.com